These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29010028)

  • 1. Tuberculosis Schemes.
    Ind Med Gaz; 1931 Sep; 66(9):522-523. PubMed ID: 29010028
    [No Abstract]   [Full Text] [Related]  

  • 2. Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in central China.
    Pan Y; Chen S; Chen M; Zhang P; Long Q; Xiang L; Lucas H
    Infect Dis Poverty; 2016 Jan; 5():7. PubMed ID: 26812914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.
    Davies GR; Khoo SH; Aarons LJ
    J Antimicrob Chemother; 2006 Sep; 58(3):594-600. PubMed ID: 16857690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic schemes in infantile tuberculosis 1966].
    Burdach R; Ibañez S; Infante R; Montes O
    Rev Chil Pediatr; 1966 Nov; 37(11):865-8. PubMed ID: 5301831
    [No Abstract]   [Full Text] [Related]  

  • 5. The need for co-operative operational research in tuberculosis control.
    Felten MK
    S Afr Med J; 1987 May; 71(10):628-30. PubMed ID: 3576382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Envisioning future strategies for vaccination against tuberculosis.
    Kaufmann SH
    Nat Rev Immunol; 2006 Sep; 6(9):699-704. PubMed ID: 16917508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tuberculosis in the rural areas of Zaire. Report on 15 years of activity in the antituberculosis center of Kisenge. Comparative study of various chemotherapeutic schemes. Conclusions in favor of ambulatory treatment. Problems of abandonment during treatment. Causes and prevention].
    Baudry A
    Acta Tuberc Pneumol Belg; 1972; 63(3):156-205. PubMed ID: 4539950
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study of immunobiological properties of specific immunomodulators of the adjuvant type in experimental tuberculosis].
    Gorelova LA; Zemskova ZS; Panasek IA; Nekrasov AV; Puchkova NG; Moroz AM; Romanova RIu
    Probl Tuberk; 1996; (3):46-7. PubMed ID: 8754882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3 therapeutic schemes to be opposed in urinary tuberculosis].
    POULAIN J
    Concours Med; 1960 Nov; 82():5039-44. PubMed ID: 13737539
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tuberculosis: a disease that is difficult to eradicate. Description of a case].
    Stazi C; Stazi F
    Clin Ter; 1990 Jul; 134(1):3-12. PubMed ID: 2147606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the dental patient with pulmonary tuberculosis.
    Díaz-Guzmán LM
    Med Oral; 2001; 6(2):124-34. PubMed ID: 11503421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revealing hidden clonal complexity in Mycobacterium tuberculosis infection by qualitative and quantitative improvement of sampling.
    Pérez-Lago L; Palacios JJ; Herranz M; Ruiz Serrano MJ; Bouza E; García-de-Viedma D
    Clin Microbiol Infect; 2015 Feb; 21(2):147.e1-7. PubMed ID: 25658553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficient drug therapy schemes for tuberculosis applicable in Latin America].
    Grinspun M
    Bol Oficina Sanit Panam; 1972 Dec; 73(6):553-60. PubMed ID: 4264522
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current concepts on the diagnosis and treatment of pulmonary tuberculosis. V. Primary schemes: drug combinations].
    Valdez-Ochoa S
    Gac Med Mex; 1974 Sep; 108(3):167-72. PubMed ID: 4455542
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug resistant pulmonary tuberculosis: problems of diagnosis and treatment in hospital conditions].
    Suslov VA; Moskalenko VA
    Voen Med Zh; 2002 May; 323(5):26-30, 112. PubMed ID: 12073833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advantages of operation of short term schemes on the conditions of the Tuberculosis Program in Mexico].
    Pacheco CR
    Salud Publica Mex; 1979; 21(5):477-85. PubMed ID: 550323
    [No Abstract]   [Full Text] [Related]  

  • 17. [Stages of the historic evolution of the antituberculosis campaign in Cuba].
    González Ochoa E; García Pérez MM; Armas Pérez L
    Rev Cubana Med Trop; 1993; 45(1):49-54. PubMed ID: 7800890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the effectiveness of contact tracing on tuberculosis outcomes in Saskatchewan using individual-based modeling.
    Tian Y; Osgood ND; Al-Azem A; Hoeppner VH
    Health Educ Behav; 2013 Oct; 40(1 Suppl):98S-110S. PubMed ID: 24084405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of cutaneous tuberculosis: primary or secondary?
    Strikas R; Venezio FR; O'Keefe JP
    Am Rev Respir Dis; 1983 Aug; 128(2):316-8. PubMed ID: 6881690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mycobacterium tuberculosis main immune response evasion mechanisms].
    Chávez-Galán L; Arenas-Del Angel Mdel C; Sada-Ovalle I; Lascurain R
    Gac Med Mex; 2009; 145(4):323-30. PubMed ID: 20073432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.